home / stock / bct:cc / bct:cc news

BCT:CC News and Press, Briacell Therapeutics Corp. From 03/20/24

Stock Information
Company Name: Briacell Therapeutics Corp.
Stock Symbol: BCT:CC
Market: TSXC
Website: briacell.com
Menu
BCT:CC BCT:CC Quote BCT:CC Short BCT:CC News BCT:CC Articles BCT:CC Message Board
Get BCT:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
BCT:CC - Canadian Companies Moving the Markets, Evening edition
Wed, Mar 20, 2024 as of 4:00 pm ET

A look at the top 10 most actives in Canada TC Energy Corporation (TRP) fell 1.1% to $54.04 on volume of 26,244,209 shares Calibre Mining Corp. (CXB) fell 7.2% to $1.68 on volume of 26,036,155 shares BetaPro Natural Gas Leveraged Daily Bull ETF (HNU) fell 3.1% to $3.78 on volume of 12,240...
BCT:CC - Canadian Companies Moving the Markets, Evening edition
Mon, Mar 18, 2024 as of 4:00 pm ET

A look at the top 10 most actives in Canada Canadian Natural Resources Limited (CNQ) rose 1.1% to $99.36 on volume of 15,927,514 shares Crescent Point Energy Corp. (CPG) rose 1.0% to $10.62 on volume of 11,545,321 shares Global Atomic Corporation (GLO) fell 30.7% to $2.17 on volume of 11,...

BCT:CC - Canadian Companies Moving the Markets, Morning edition
Thu, Mar 14, 2024 as of 10.00 am ET

A look at the top 10 most actives in Canada Lundin Mining Corporation (LUN) fell 0.1% to $12.7 on volume of 10,285,870 shares Canadian Natural Resources Limited (CNQ) fell 0.6% to $99.01 on volume of 6,570,639 shares TC Energy Corporation (TRP) fell 1.0% to $54.51 on volume of 4,227,716 s...

BCT:CC - Canadian Companies Moving the Markets, Evening edition
Thu, Mar 07, 2024 as of 4:00 pm ET

A look at the top 10 most actives in Canada Cenovus Energy Inc. (CVE) fell 0.0% to $24.15 on volume of 11,784,891 shares BetaPro Natural Gas Leveraged Daily Bull ETF (HNU) fell 13.4% to $4.15 on volume of 11,675,241 shares Bitfarms Ltd. (BITF) fell 6.4% to $3.36 on volume of 9,646,374 sha...
BCT:CC - BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies

Agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ (breast cancer) and Bria-PROS+ (prostate cancer), BriaCell’s novel off-the-shelf personalized cancer vaccines, marks a major milestone for BriaCell PHILADELPHIA and VANCOUVER, British...

BCT:CC - BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference

PHILADELPHIA and VANCOUVER, British Columbia, March 06, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer c...

BCT:CC - BriaCell Provides Update on Alleged Illegal Trading of Public Securities

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology  company that develops novel immunotherapies t...
BCT:CC - Canadian Companies Moving the Markets, Evening edition
Thu, Feb 15, 2024 as of 4:00 pm ET

A look at the top 10 most actives in Canada Athabasca Oil Corporation (ATH) rose 4.4% to $4.53 on volume of 16,671,730 shares Bitfarms Ltd. (BITF) fell 1.9% to $4.64 on volume of 16,479,587 shares Manulife Financial Corporation (MFC) rose 8.9% to $33.41 on volume of 14,401,422 shares Ce...

BCT:CC - Canadian Companies Moving the Markets, Evening edition
Wed, Feb 14, 2024 as of 4:00 pm ET

A look at the top 10 most actives in Canada Bitfarms Ltd. (BITF) rose 15.2% to $4.69 on volume of 17,583,238 shares Enbridge Inc. (ENB) fell 2.5% to $45.2 on volume of 9,273,780 shares BetaPro Natural Gas Leveraged Daily Bull ETF (HNU) fell 7.1% to $3.66 on volume of 8,920,485 shares iS...

BCT:CC - BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case

Disease control rate of 61% observed in evaluable Phase 2 patients treated with the same formulation in BriaCell’s pivotal Phase 3 study Disease control rate of 50% in evaluable patients treated with the Phase 3 formulation who failed prior antibody-drug conjugate (ADC) therapy...
Previous 10 Next 10